Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Videos

Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
Videos
Inflammatory Oligodendrocyte Precursor Cells and Remyelination in MS
10/06/2020
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi, MD, discusses the findings from his award-winning study, which suggested that inhibiting immune activation of oligodendrocyte precursor cells may foster remyelination among patients with multiple sclerosis. Dr...
In this video, Peter Calabresi,...
10/06/2020
Neurology
Managing MS During the Pandemic: DMTs, Telemedicine, and More
Videos
Managing MS During the Pandemic: DMTs, Telemedicine, and More
09/30/2020
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia Nourbakhsh, MAS, MD, gives an overview of how COVID-19 has changed how he and his colleagues see and treat patients with multiple sclerosis in their tertiary specialty care center, and the challenges that have arisen...
In this video, Bardia...
09/30/2020
Neurology
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Psychotropic Treatment Classes and Options
Videos
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: Psychotropic Treatment Classes and Options
09/18/2020
In this video, Laura T. Safar, MD, gives an overview of psychotropic treatment classes, their uses in the management of neuropsychiatric disorders among patients with multiple sclerosis, and important considerations for each class. She...
In this video, Laura T. Safar, MD, gives an overview of psychotropic treatment classes, their uses in the management of neuropsychiatric disorders among patients with multiple sclerosis, and important considerations for each class. She...
In this video, Laura T. Safar,...
09/18/2020
Neurology

Advertisement
Videos
Dawn Buse, PhD, on the OVERCOME Study
09/14/2020
In this video, Dr Buse discusses the findings of the OVERCOME Study, in which she and her colleagues investigated the influence of acute treatment optimization on disability and health-related quality of life among people with migraine.
In this video, Dr Buse discusses the findings of the OVERCOME Study, in which she and her colleagues investigated the influence of acute treatment optimization on disability and health-related quality of life among people with migraine.
In this video, Dr Buse discusses...
09/14/2020
Neurology
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: The Role of Psychotropics
Videos
Neuropsychiatric Disorders Among Patients With Multiple Sclerosis: The Role of Psychotropics
09/13/2020
In this video, Laura T. Safar, MD, discusses psychotropic treatment as one of several potential tools for the management of neuropsychiatric disorders among patients with multiple sclerosis.
In this video, Laura T. Safar, MD, discusses psychotropic treatment as one of several potential tools for the management of neuropsychiatric disorders among patients with multiple sclerosis.
In this video, Laura T. Safar,...
09/13/2020
Neurology
Videos
Urvish Patel, MD, on Status Migrainosus Triggers and Impact on Morbidity
09/09/2020
In this video, Dr Patel discusses the findings from his study on the the role of triggers in status migrainosus and its association with morbidity. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In this video, Dr Patel discusses the findings from his study on the the role of triggers in status migrainosus and its association with morbidity. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In this video, Dr Patel...
09/09/2020
Neurology

Advertisement

Key Takeaways from the PROMISE-2 Trial of Eptinezumab for Migraine
Videos
Key Takeaways from the PROMISE-2 Trial of Eptinezumab for Migraine
09/09/2020
In this video, Richard Lipton, MD, reviews key findings from the PROMISE-2 trial of eptinezumab for the treatment of chronic migraine.
In this video, Richard Lipton, MD, reviews key findings from the PROMISE-2 trial of eptinezumab for the treatment of chronic migraine.
In this video, Richard Lipton,...
09/09/2020
Neurology
Advantages of Intravenous Eptinezumab in the Treatment of Migraine
Videos
Advantages of Intravenous Eptinezumab in the Treatment of Migraine
09/09/2020
In this video, Richard Lipton, MD, discusses evidence of the effects of intravenous eptinezumab compared with other monoclonal antibodies that are FDA-approved for migraine.
In this video, Richard Lipton, MD, discusses evidence of the effects of intravenous eptinezumab compared with other monoclonal antibodies that are FDA-approved for migraine.
In this video, Richard Lipton,...
09/09/2020
Neurology
Important Research Advances in the Clinical Science of Concussion
Videos
Important Research Advances in the Clinical Science of Concussion
09/05/2020
In this video, Christina L. Master, MD, discusses recently published research on disparities in sports concussion when it comes to availability of flag football vs tackle football, the impact of active specialized sports medicine care vs a...
In this video, Christina L. Master, MD, discusses recently published research on disparities in sports concussion when it comes to availability of flag football vs tackle football, the impact of active specialized sports medicine care vs a...
In this video, Christina L....
09/05/2020
Neurology

Advertisement

Chronic Migraine: How Eptinezumab Affects Headache Impact Test-6 Scores
Videos
Chronic Migraine: How Eptinezumab Affects Headache Impact Test-6 Scores
08/28/2020
In this video, Richard Lipton, MD, discusses the results of the PROMISE-2 trial, including the observed reductions in Headache Impact Test-6 (HIT-6) total and item scores among patients with chronic migraine who were treated with eptinezumab.
In this video, Richard Lipton, MD, discusses the results of the PROMISE-2 trial, including the observed reductions in Headache Impact Test-6 (HIT-6) total and item scores among patients with chronic migraine who were treated with eptinezumab.
In this video, Richard Lipton,...
08/28/2020
Neurology

Advertisement

Advertisement

News

Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
News
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
08/08/2024
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive...
08/08/2024
Neurology
brain waves
News
High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke
08/08/2024
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose...
08/08/2024
Neurology
An illustration of a healthcare provider conducting a telehealth appointment
News
Teleneurology Visits Acceptable to Patients Across Neurologic Conditions
08/05/2024
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic...
08/05/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
DMD Gene Therapy Indication Expanded to Include Boys 4 and Older
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
News
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
07/23/2024
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug...
07/23/2024
Neurology
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
News
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
07/22/2024
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was...
07/22/2024
Neurology
a hand breaks a wooden human figurine in half
News
Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related...
07/18/2024
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use